Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. Its lead product, AXS-05, is being evaluated for treatment-resistant depression and has shown promising efficacy in clinical trials, positioning the company to capture significant market share in a high-demand therapeutic area.
Axsome generates revenue primarily through the sale of its CNS therapies, with AXS-05 expected to be a significant contributor upon commercialization. The company benefits from high gross margins (92.6%) due to the nature of biopharmaceutical sales, and it has a strong pipeline that enhances its pricing power and competitive position in the market.
Clinical trial results for AXS-05, particularly Phase 3 outcomes
FDA approval timelines and outcomes for AXS-05 and other pipeline candidates
Partnership announcements or licensing deals with larger pharmaceutical companies
Market adoption rates of AXS-05 post-launch
Regulatory changes affecting drug approval processes and pricing
Technological disruption in drug development methodologies
Emergence of alternative therapies for CNS disorders from competitors
Potential patent expirations affecting exclusivity of AXS-05
High debt levels could limit financial flexibility
Negative cash flow could necessitate additional financing
moderate - As a biotech firm, Axsome's performance can be influenced by overall healthcare spending, which is correlated with GDP growth and consumer spending, particularly in the CNS treatment market.
Rising interest rates could increase financing costs for Axsome, impacting its ability to fund R&D and operational expenses, although the company is primarily equity-financed.
minimal - The company has a high debt/equity ratio (3.97), but its operations are not heavily reliant on credit markets.
growth - Investors are likely attracted to Axsome due to its high revenue growth potential and innovative pipeline.
high - The stock has demonstrated significant volatility, with a 1-year return of 145.1%, reflecting the high-risk, high-reward nature of biotech investments.
